|
|
|
|
Department of Experimental Therapeutics, Grace Cancer Drug Center,
Roswell Park Cancer Institute, Buffalo, New York 14263
In a previous study, we found that treatment of HCT-8 cells with
ZD1694, a specific antifolate-based thymidylate synthase inhibitor,
resulted in DNA fragmentation. In this study, we have demonstrated the
dose- and time-dependent induction of DNA fragmentation accompanied by
elevation of p53 and WAF1 protein expression by ZD1694. WAF1 mRNA
showed a time-dependent increase, whereas p53 mRNA was not found to be
significantly overexpressed. The initial increase in WAF1 mRNA was
detected at 4 hr, but increased WAF1 protein expression was detected
8-24 hr after a 2-hr exposure. The amount of total and
hypophosphorylated pRb seems to be rising greatly after ZD1694
exposure. The effects of ZD1694 on the expression of E2F1 and formation
of the E2F1-Rb complex were investigated after a 2-hr drug exposure
(IC90). The results showed a time-dependent decrease in
E2F1 mRNA and protein expression; an increase in the abundance of the
E2F-Rb complex could be demonstrated beginning 4 hr after drug exposure
by a gel shift assay. Kinetic analysis showed increased availability of
hypophosphorylated pRb for inhibition of E2F, which could indirectly
result from WAF1-induced inhibition cyclin-dependent kinase activity.
Whereas thymidylate synthase inhibition by ZD1694 was rapid in onset
and maintained for at least 24 hr after drug treatment, drug-induced
cellular growth inhibition was significant 24 hr after drug exposure.
The increased abundance of hypophosphorylated pRb and binding to
transcription factor E2F-1 is consistent with ZD1694-induced cell
growth inhibition in HCT-8 cells. Therefore, the observed effect on
downstream events after effective inhibition of thymidylate synthase
may offer the critical determinants of response to ZD1694.
This article has been cited by other articles:
![]() |
K. Tsukiyama-Kohara, S. Tone, I. Maruyama, K. Inoue, A. Katsume, H. Nuriya, H. Ohmori, J. Ohkawa, K. Taira, Y. Hoshikawa, et al. Activation of the CKI-CDK-Rb-E2F Pathway in Full Genome Hepatitis C Virus-expressing Cells J. Biol. Chem., April 9, 2004; 279(15): 14531 - 14541. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Bronder and R. G. Moran A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition J. Biol. Chem., December 5, 2003; 278(49): 48861 - 48871. [Abstract] [Full Text] [PDF] |
||||